Summary
McKesson Corporation reported solid revenue growth for the third quarter and the first nine months of fiscal year 2020, driven by market expansion and increased drug utilization. However, the company experienced a significant decline in net income attributable to McKesson Corporation, largely due to a substantial impairment charge related to its investment in Change Healthcare Joint Venture. Despite this, the company's core operations in U.S. Pharmaceutical and Specialty Solutions showed improved operating profit. Investors should note the ongoing litigation and investigations, particularly concerning opioid distribution, which present a significant contingent liability. The company also announced a planned tax-efficient exit from its Change Healthcare investment.
Financial Highlights
51 data points| Revenue | $59.17B |
| Cost of Revenue | $56.14B |
| Gross Profit | $3.03B |
| Operating Expenses | $2.67B |
| Operating Income | $360.00M |
| Net Income | $186.00M |
| EPS (Basic) | $1.04 |
| EPS (Diluted) | $1.03 |
| Shares Outstanding (Basic) | 178.70M |
| Shares Outstanding (Diluted) | 179.70M |
Key Highlights
- 1Revenues increased by 5% to $59.2 billion for the three months ended December 31, 2019, and by 7% to $172.5 billion for the nine months ended December 31, 2019.
- 2Net income attributable to McKesson Corporation decreased significantly to $186 million for the quarter, compared to $469 million in the prior year, impacted by a $1.2 billion other-than-temporary impairment charge on its Change Healthcare JV investment.
- 3The U.S. Pharmaceutical and Specialty Solutions segment reported an operating profit of $687 million for the quarter, a 2% increase year-over-year, indicating strong performance in its core business.
- 4The company incurred substantial charges related to restructuring, impairment, and ongoing opioid litigation, impacting overall profitability.
- 5McKesson plans a tax-efficient exit from its investment in Change Healthcare Joint Venture.
- 6The company maintained compliance with its debt-to-capital ratio covenant and continued to return capital to shareholders through dividends and share repurchases.